XML 104 R66.htm IDEA: XBRL DOCUMENT v2.4.0.6
ACQUISITIONS (Details) (USD $)
In Millions, unless otherwise specified
 12 Months Ended
Dec. 31, 2011
Amira Pharmaceuticals [Member]
Dec. 31, 2010
Zymogenetics, Inc [Member]
Dec. 31, 2010
Zymogenetics, Inc [Member]
Other Intangible Assets [Member]
Dec. 31, 2010
Zymogenetics, Inc [Member]
Pegylated Interferon Lambda [Member]
Dec. 31, 2009
Medarex, Inc. [Member]
Dec. 31, 2009
Medarex, Inc. [Member]
Celldex Therapeutics, Inc. [Member]
Dec. 31, 2009
Medarex, Inc. [Member]
Genmab Inc [Member]
Dec. 31, 2009
Medarex, Inc. [Member]
Other Intangible Assets [Member]
Dec. 31, 2009
Medarex, Inc. [Member]
Licenses [Member]
Dec. 31, 2009
Medarex, Inc. [Member]
YERVOY [Member]
Acquisition [Line Items]                    
Percentage of outstanding shares acquired 100.00% 100.00%     100.00%          
Acquisition costs $ 1 $ 10     $ 11          
Purchase price paid in cash 325 885                
Fair value of contingent consideration 58                  
Fair value of the Company's equity in Medarex held prior to acquisition         46          
Aggregate purchase price 383 885     2,331          
Number of contingent milestone payments 3                  
Contingent milestone payment amount 50                  
Purchase price allocation - Cash 15 56     53          
Purchase price allocation - Marketable securities   91     269          
Purchase price allocation - Inventory   98                
Purchase price allocation - Other current and long-term assets   29     127          
Purchase price allocation - In-process research and development 160 448   310 1,475         1,000
Purchase price allocation - Intangible assets     230         120 217  
Purchase Price Allocation - Short-term borrowings         (92)          
Purchase price allocation - Accrued expenses (16)                  
Purchase price allocation - Deferred income taxes (41) 9     (318)          
Purchase price allocation - Other current and long-term liabilities   (91)     (92)          
Purchase price allocation - Total identifiable net assets 118 870     1,759          
Purchase price allocation - Goodwill 265 15     572          
Purchase price allocation - Long term inventory   63                
Other income recognized from the remeasurement to fair value of the equity interest in the acquiree held at the acquisition date         21          
Ownership interest percentage in investments included in other current and long-term assets           18.70% 5.10%      
Ownership interest in investments included in other current and long-term assets           17 64      
Realized loss on sale of securities         $ 33